FUJIFILM Biotechnologies has introduced ShunzymeX precision purification technology, designed to enhance downstream processing for complex biologics. This innovative solution is set to be showcased at the Festival of Biologics conference in San Diego, highlighting its potential impact on the industry.
Developed in collaboration with the University of Edinburgh, ShunzymeX utilizes a proprietary protease that simplifies the purification of complex biologics by incorporating an affinity tag. This feature allows for the use of standard affinity resins, and the protease subsequently cleaves the tag without damaging the native protein. The technology aims to accelerate process development, enabling clients to meet GMP manufacturing and IND-enabling milestones more efficiently.
ShunzymeX addresses the challenges of traditional microbial purification, which often suffers from variability in protein characteristics, leading to lengthy development times and low yields. By streamlining purification processes, ShunzymeX can significantly reduce development timelines and is compatible with various expression systems, ensuring scalability to cGMP standards. The technology’s introduction is poised to facilitate faster commercialization pathways for biopharmaceuticals, as emphasized by FUJIFILM’s leadership.
Open the full market picture for your next decision →
